BioMarin upgraded at Credit Suisse As previously reported, Credit Suisse upgraded BioMarin to Outperform from Neutral. The firm upgraded shares due to share declines and sees potential catslysts ahead that include BMN 111 Ph I/II results in Q2 2015, BMN 190 and PEG-PAL results in late 2015 and Ph III BMN-701 enrollment in 1H 2015. Price target remains $73.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.